Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Liquidia Corporation

In a report released today, from Wells Fargo assigned a Buy rating to Liquidia Technologies, with a price target of $51.00. In addition to Wells Fa...

Market Cap	$2.29B	P/E Ratio	23.04
52W High	$46.67	52W Low	$11.26
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-33.4%	52W Position	82.1%
Overall Score	56	Value Score	40
Quality Score	60	Technical Score	70

EPS Current Est	$1.75	EPS Next Est	$2.91
EPS Growth Est	+66.3%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LQDA	$40.32	+5.58%	1.21M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LQDA	$40.32	+5.6%	1.21M
3
4
5
6

LQDA

LQDA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Liquidia Corporation Data in Excel

Get Liquidia Corporation Data in Excel